Expanded access program for Entasis' sulbactam-durlobactam in USA
USA-based antibacterial products developer Entasis Therapeutics (Nasdaq: ETTX) has announced the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for US patients with Acinetobacter baumanni infections, including carbapenem and multidrug resistant strains.
Entasis’ share price closed up 2.6% at $3.53 following the announcement yesterday.
“The ability to provide access to patients in need is consistent with the Entasis mission,” said Dr David Altarac, chief medical officer of Entasis, a 2015 spin-out from Anglo-Swedish pharma major AstraZeneca (LSE: AZN). “We are excited to have in place an EAP for patients who are not eligible to participate in our study and who are suffering from a serious and life-threatening infection caused by drug resistant Acinetobacter,” he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze